Positive FDA Pre-IND Feedback Announced for SVC112 Program in Advanced Solid Tumors
“We are very encouraged by the FDA’s feedback and believe this represents an important milestone in the development of SVC112,” said Antonio Jimeno, MD, PhD, CU Anschutz Professor, Medicine-Medical Oncology, and Board member of SuviCa. “The Agency’s responses support our development strategy and provide a clear regulatory path toward IND submission and initiation of our first-in-human clinical study, added Dr. Jimeno. “The innovative support network at the University of Colorado’s Boulder and Anschutz campuses has made all this possible,” said Tin Tin Su, PhD, CU Boulder Professor, lead inventor of SVC112, and co-founder of SuviCa.
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000